Nicox is up almost 10% on the Paris Bourse this Wednesday, following the presentation of new data on two of its compounds.

The ophthalmology specialist reports that non-clinical work on its NCX 470 eye drop has provided 'convincing' new evidence of the product's protective activity on retinal cells, in addition to its ability to reduce intraocular pressure (IOP).

NCX 470, a novel nitric oxide-donating bimatoprost eye drop, is currently in phase 3 clinical development for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.

At the same time, data on NCX 1728 indicate that stimulation of the soluble nitric oxide/guanylyl cyclase signaling pathway is the main contributor to these effects.

According to Nicox, these data mean that NCX 1728 could show promise in the treatment of retinopathies in which ocular perfusion dysfunction and neovascularization are key pathophysiological features in disease progression.

These data were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), currently being held in New Orleans, Louisiana.

Note that the transfer of listing from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility will take effect on Friday.

Copyright (c) 2023 CercleFinance.com. All rights reserved.